MT-303(Myeloid)

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameMT-303(Myeloid)

Drug Alias NameMT-303(Create Medicines)GPC3-FcA LNPMT-303(Myeloid)

ClassificationCell and gene therapy > Cell therapy > In vivo cell therapyCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > mRNA +[4]

Mechanisms of ActionAnti-Glypican-3

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwanAustraliaSouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMyeloid Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMyeloid Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A